IRVINE, Calif.— Allergan (NYSE: AGN) announced that it generated total product net sales of $1,391.1 million for the quarter ended Sept. 30, 2012, a 6.1 percent increase over third quarter 2011. On a constant currency basis, total product net sales increased 9.4 percent compared to total product net sales in the third quarter of 2011.

Total specialty pharmaceuticals net sales increased 8.1 percent, or 11.4 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the third quarter of 2011, Allergan said. Total medical devices net sales decreased 4.0 percent, or 0.3 percent on a constant currency basis, compared to total medical devices net sales in the third quarter of 2011.

"In the third quarter, Allergan again delivered solid earnings growth in spite of the strong U.S. dollar relative to virtually all major currencies," said David E.I. Pyott, Allergan's chairman of the board, president and CEO.